Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-548aq-3p inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-548aq-3p inhibitor is an experimental antisense RNA therapy designed to target and neutralize miR-548aq-3p, a microRNA implicated in chemotherapy resistance. In epithelial ovarian cancer, miR-548aq-3p is secreted in exosomes and downregulates the RNA polymerase II mediator complex subunit 12 (MED12), leading to reduced cisplatin sensitivity. By sequestering miR-548aq-3p, the inhibitor restores MED12 levels, promotes apoptosis in cisplatin-resistant cells, and enhances the efficacy of platinum-based chemotherapy.
- Other names
- anti-miR-548aq-3panti-miR548aq-3panti-miR 548aq-3pmiR-548aq-3p antagomirmiR548aq-3p antagomirmiR 548aq-3p antagomir
Beyond the preview
Go deeper on miR-548aq-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-548aq-3p inhibitor.